{"schema_version":"secwatch.filing_event.v1","accession":"0001736730-25-000111","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.281595+00:00","generated_at":"2026-05-16T12:45:53.746036+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CAMP4 enters collaboration with GSK for ASO therapeutics; $17.5M upfront, up to $440M milestones","bullets":["Collaboration with GSK to discover ASO therapeutics for neurodegenerative and kidney diseases using CAMP4's RAP Platform.","CAMP4 receives $17.5M upfront; eligible for up to $440M in milestone payments plus tiered royalties.","CAMP4 performs research to identify and deliver lead ASO series; GSK responsible for development and commercialization.","Tiered royalties on annual net sales range from low- to mid-single digits; royalty term per product defined."],"urls":{"canonical":"https://secwatch.observer/filing/0001736730-25-000111","json":"https://secwatch.observer/filing/0001736730-25-000111.json","markdown":"https://secwatch.observer/filing/0001736730-25-000111.md","text":"https://secwatch.observer/filing/0001736730-25-000111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000111/0001736730-25-000111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000111/camp-20251217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:45:53.746036+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"817f6aa1d59548a8872d9e51b5840a64487b5c04","claim":"Camp4 Therapeutics Corp entered into Research, Collaboration and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited valued at $17.5 million (effective 2025-12-17).","evidence_excerpt":"On December 17, 2025, CAMP4 Therapeutics Corporation (the “Company”) entered into a Research, Collaboration and License Agreement (the “Agreement”) with GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000111/0001736730-25-000111-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"GlaxoSmithKline Intellectual Property (No. 3) Limited"},{"label":"Value","value":"$17.5 million"},{"label":"Effective","value":"2025-12-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}